Update On FDA Advisory Committee Vote On Camizestrant In Combination With A CDK4/6 Inhibitor For Advanced HR-Positive Breast Cancer; AstraZeneca Says FDA Did Not Reach Majority Vote On Benefit Risk Profile Of AstraZeneca's Camizestrant In Combination With CDK4/6 Inhibitor